Clinical genitourinary cancer最新文献

{"title":"Risk Stratification for the Prognosis of Patients With pT3aN0M0 Clear Cell Renal Cell Carcinoma","authors":"Shigeki Koterazawa ,&nbsp;Takayuki Sumiyoshi ,&nbsp;Katsuhiro Ito ,&nbsp;Kimihiko Masui ,&nbsp;Atsushi Igarashi ,&nbsp;Koji Inoue ,&nbsp;Noriyuki Ito ,&nbsp;Noboru Shibasaki ,&nbsp;Takaaki Takuma ,&nbsp;Masakatsu Ueda ,&nbsp;Takehiro Yamane ,&nbsp;Ken Maekawa ,&nbsp;Sojun Kanamaru ,&nbsp;Akihiro Hoshiyama ,&nbsp;Toru Kanno ,&nbsp;Yoshio Sugino ,&nbsp;Kazuma Hiramatsu ,&nbsp;Toru Yoshida ,&nbsp;Shuhei Koike ,&nbsp;Kazutoshi Okubo ,&nbsp;Takashi Kobayashi","doi":"10.1016/j.clgc.2025.102400","DOIUrl":"10.1016/j.clgc.2025.102400","url":null,"abstract":"<div><h3>Background</h3><div>Predicting postoperative recurrence in patients with pathological T3aN0M0 clear cell renal cell carcinoma (pT3a ccRCC) is important to identify patients suitable for adjuvant immunotherapy. This study aimed to develop a novel predictive model for postoperative recurrence of pT3a ccRCC.</div></div><div><h3>Materials and Methods</h3><div>Patients diagnosed with pT3a ccRCC between 2010 and 2022 were retrospectively enrolled from 19 institutions. Multivariable Cox proportional hazards regression was used to identify clinical factors associated with poor disease-free survival (DFS). A risk model was established based on the hazard ratios of the identified factors. DFS and overall survival were calculated using the Kaplan-Meier method according to the risk group. The association between the risk model categories and the International Metastatic RCC Database Consortium (IMDC) score at recurrence was also evaluated using the chi-square test.</div></div><div><h3>Results</h3><div>This study included 541 patients with pT3a ccRCC. With a median follow-up of 46 months, postoperative recurrence occurred in 165 (30.5%) patients and death occurred in 81 (15.0%) patients. Multivariate analysis identified 6 variables associated with shorter DFS: male sex, ≥3 extrarenal tumor extension patterns, tumor size &gt;70 mm, nuclear grade 3 or 4, sarcomatoid differentiation, and C-reactive protein ≥1.0 mg/L. The predictive model classified patients into low-, intermediate-, and high-risk categories, with 5-year DFS rates of 88%, 67%, and 39%, respectively. The area under the curve for the 5-year DFS was 0.752. At recurrence, half of the patients in the low-risk group were classified in the IMDC-favorable group, compared to 23.1% in the high-risk group.</div></div><div><h3>Conclusions</h3><div>This risk model can predict postoperative recurrence risk in patients with pT3a ccRCC. This model may help in selecting candidates for adjuvant therapy for pT3aN0M0 ccRCC.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 5","pages":"Article 102400"},"PeriodicalIF":2.7,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144762680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Surgical Outcomes of Bladder Paraganglioma: A 20-Year Nationwide Center Experience","authors":"Wencong Han ,&nbsp;Xiaoteng Yu ,&nbsp;Shiwei Chen ,&nbsp;Zejin Ou ,&nbsp;Tai Kang ,&nbsp;Zheng Zhang","doi":"10.1016/j.clgc.2025.102397","DOIUrl":"10.1016/j.clgc.2025.102397","url":null,"abstract":"<div><h3>Objective</h3><div><strong>:</strong> Bladder paraganglioma (BPGL) is a rare neuroendocrine tumor. This study evaluates the clinical characteristics, perioperative course, and long-term outcomes of BPGL treated at a nationwide center over the past 2 decades.</div></div><div><h3>Methods</h3><div>A retrospective review was conducted on 45 patients who underwent surgery for BPGL between January 2004 and September 2024. Demographic data, clinical features, tumor characteristics, surgical approach, intraoperative hemodynamic instability (HDI), and follow-up outcomes were assessed.</div></div><div><h3>Results</h3><div>The median age of patients was 54.0 years (IQR, 36.5, 65.0), with 66.4% being female. A preoperative diagnosis was made in 53.3% of cases. Younger patients (age ≤40 years) exhibited more catecholamine-related symptoms (75.0% vs. 24.2%, <em>P</em> = .006), larger tumor sizes (4.3 cm vs. 1.8 cm, <em>P</em> = .010), higher plasma normetanephrine levels (14.0 nmol/L vs. 1.9 nmol/L, <em>P</em> = .014), were more likely to be diagnosed preoperatively (83.3% vs. 42.4%, <em>P</em> = .015), and had a higher rate of metastasis (41.7% vs. 3.0%, <em>P</em> = .004) compared to older patients. Intraoperative HDI occurred in 51.1% of patients. Prolonged anesthesia (189.0 min vs. 97.5 min, <em>P</em> = .013) and surgery time (134.0 min vs. 25.5 min, <em>P</em> = .005) were significantly associated with HDI. The median follow-up time was 5.1 years (IQR, 1.4-8.3 years), during which 1 patient (2.4%) experienced recurrence, and 1 patient (2.4%) died from the disease. No other patients experienced recurrence or metastasis.</div></div><div><h3>Conclusion</h3><div>Younger age predicts more aggressive BPGL behavior. Transurethral resection (TUR) is a safe and effective option for tumors ≤3 cm. Early recognition, meticulous perioperative management and lifelong surveillance are essential to optimize outcomes.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 5","pages":"Article 102397"},"PeriodicalIF":2.7,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144770611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Lutetium-177 PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","authors":"Zineddine Belabaci ,&nbsp;Mouhammed Sleiay ,&nbsp;Abdelrahman Abdelshafi ,&nbsp;Zina Otmani ,&nbsp;Elsayed S. Moubarak ,&nbsp;Faten Amer","doi":"10.1016/j.clgc.2025.102398","DOIUrl":"10.1016/j.clgc.2025.102398","url":null,"abstract":"<div><h3>Background and aim</h3><div>Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy using lutetium-177 has emerged as a promising treatment for metastatic castration-resistant prostate cancer (mCRPC). In this systematic review and meta-analysis, the safety and efficacy of PSMA-targeted radioligand therapy (PRLT) using lutetium-177 ([¹⁷⁷Lu]Lu-PSMA) were assessed.</div></div><div><h3>Methods</h3><div>This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. A detailed searches were conducted across PubMed, EMBASE, Cochrane Library and Scopus for randomized controlled trials (RCTs) on [177Lu]Lu-PSMA radioligand therapy in mCRPC. Prostate-specific antigen (PSA) responses, toxicity profiles, and outcomes including radiographic progression-free survival (rPFS) and overall survival were assessed. Quantitative analyses with Review Manager 5.4 software, using Risk estimates (hazard ratios, RR and OR) and 95% confidence intervals for outcomes in random effects were performed.</div></div><div><h3>Results</h3><div>Six RCTs involving 2113 patients with mCRPC were included in the meta-analysis. Patients treated with [¹⁷⁷Lu]Lu-PSMA had a significantly higher response to therapy compared to controls based on ≥50% PSA decrease (OR = 4.27; 95% confidence interval [CI]: 2.59-7.06; <em>P</em> &lt; .00001) and objective response rate (ORR) (RR=2.93; 95% CI, 1.62-5.30; <em>P</em> = .0004). [¹⁷⁷Lu]Lu-PSMA reduced the risk of rPFS (HR=0.57; 95% CI, 0.46-0.70; <em>P</em> &lt; .00001). However, no significant impact on overall survival was observed (HR = 0.81; 95% CI, 0.62-1.06; <em>P</em> = .13). No significant difference in grade ≥3 adverse events was reported (RR = 0.85; 95% CI, 0.63-1.15; <em>P</em> = .32).</div></div><div><h3>Conclusion</h3><div>These findings support the use of [¹⁷⁷Lu]Lu-PSMA for metastatic castration-resistant prostate cancer, demonstrating both safety profile and efficacy. The potential of this therapeutic approach warrants further investigative efforts to optimize treatment methodologies and improve the quality of patient care and the criteria for patient selection.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 5","pages":"Article 102398"},"PeriodicalIF":2.7,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144723874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of gastrectomy on cabozantinib exposure: Clinical case of a patient with clear renal cell carcinoma","authors":"Sanae Kdadri ,&nbsp;Fabien Moinard-Butot ,&nbsp;Antonin Schmitt ,&nbsp;Bernard Royer ,&nbsp;Philippe Barthélémy","doi":"10.1016/j.clgc.2025.102396","DOIUrl":"10.1016/j.clgc.2025.102396","url":null,"abstract":"<div><div>This case report describes the pharmacokinetic (PK) alterations of cabozantinib in a gastrectomised patient with metastatic renal cell carcinoma (mRCC). The patient, who had previously been treated with cabozantinib, underwent a gastrectomy due to complications from a diaphragmatic hernia. After disease progression, cabozantinib was reintroduced at a reduced dose of 40 mg daily. PK analysis revealed early absorption and rapid elimination of the drug compared to typical profiles, suggesting that gastric resection impacts cabozantinib’s absorption and clearance. These findings indicate that standard dosing regimens may not be appropriate for gastrectomised patients, emphasizing the need for personalized dose adjustments. This case highlights the importance of pharmacokinetic (PK) monitoring to optimize treatment outcomes in this patient population and suggests further research on the broader impact of gastrectomy on tyrosine kinase inhibitors (TKI).</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 5","pages":"Article 102396"},"PeriodicalIF":2.7,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144722365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Assessment of Chemotherapy Followed by Consolidative Radical Cystectomy Versus Chemoradiation for Clinically Node-Positive Urothelial Carcinoma of the Bladder","authors":"Aleksander Ślusarczyk ,&nbsp;Pietro Scilipoti ,&nbsp;Roberto Contieri ,&nbsp;Mattia Longoni ,&nbsp;Mario de Angelis ,&nbsp;Marcin Miszczyk ,&nbsp;Wojciech Krajewski ,&nbsp;Ekaterina Laukthina ,&nbsp;Francesco Del Giudice ,&nbsp;Andrea Gallioli ,&nbsp;Paweł Rajwa ,&nbsp;Benjamin Pradere ,&nbsp;Paras Shah ,&nbsp;Stephen A. Boorjian ,&nbsp;Marco Moschini ,&nbsp;Piotr Radziszewski","doi":"10.1016/j.clgc.2025.102399","DOIUrl":"10.1016/j.clgc.2025.102399","url":null,"abstract":"<div><h3>Context</h3><div>Patients with bladder cancer and clinically positive pelvic lymph nodes (cN+) have poor prognosis, and the optimal definitive treatment method remains controversial.</div></div><div><h3>Objective</h3><div>To compare survival outcomes between chemotherapy followed by radical cystectomy (RC) and chemoradiation (CRT) in patients with cN+ bladder cancer.</div></div><div><h3>Methods</h3><div>We queried the Surveillance, Epidemiology, and End Results (2000-2021) database to identify patients with cN+ bladder cancer treated with CRT or chemotherapy and RC. Cumulative incidence functions, Fine–Gray model, and Cox proportional hazards were used for the survival analysis. Inverse probability treatment weighting (IPTW) was used to adjust for confounders. The primary endpoints were cancer-specific mortality (CSM) and all-cause mortality (ACM).</div></div><div><h3>Results</h3><div>Among 552 patients identified, 175 (32%) received CRT and 377 (68%) underwent chemotherapy plus RC, and 5-year ACM was 75% (95% confidence interval [CI]: 71%-78%). RC and CRT were associated with 5-year CSM of 62% (95% CI: 57%-67%) and 72% (95% CI: 65%-78%), and 5-year ACM of 70% (95% CI: 65%-75%) and 85% (95% CI: 75%-90%), respectively. After IPTW, on multivariable Cox proportional hazard analysis adjusted for nodal and tumor staging, age, gender, tumor size and race, RC was associated with a significantly lower risk of CSM (hazard ratio [HR]: 0.47, 95% CI: 0.37-0.60, <em>P</em> &lt; .001) and ACM (HR: 0.53, 95% CI: 0.46-0.60, <em>P</em> &lt; .001).</div></div><div><h3>Conclusions</h3><div>Patients with cN+ bladder cancer who received CRT had a worse prognosis compared to those who underwent chemotherapy followed by RC. The incorporation of more effective systemic therapies is required to improve outcomes, as in our analysis, only one in four cN+ patients survived beyond 5 years.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 5","pages":"Article 102399"},"PeriodicalIF":2.7,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144723873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Disparities by Sex, Race, and Age in the Era of Contemporary Advanced Urothelial Carcinoma Therapy: A Real-World Analysis","authors":"Adam A. Barsouk ,&nbsp;Austin Yang ,&nbsp;Jonathan H. Sussman ,&nbsp;Omar Elghawy ,&nbsp;Jessica Xu ,&nbsp;Jason Xu ,&nbsp;Lingbin Meng ,&nbsp;Shunsuke Koga ,&nbsp;Wei Du ,&nbsp;Ronac Mamtani ,&nbsp;Lin Mei","doi":"10.1016/j.clgc.2025.102395","DOIUrl":"10.1016/j.clgc.2025.102395","url":null,"abstract":"<div><h3>Introduction</h3><div>Retrospective data suggest poorer survival for female, racial minority, and older advanced urothelial carcinoma (aUC) patients. However, data on survival disparities in the modern era remain limited.</div></div><div><h3>Methods</h3><div>This cohort study used Flatiron Health’s nationwide de-identified electronic health record (EHR)-derived database. Patients who initiated systemic therapy for aUC between January, 2017 and May, 2024 were included. Baseline characteristics, treatment history, and clinical outcomes were abstracted. PFS and OS were compared by sex (male vs. female), race (White, Black, vs. Asian/Pacific Islander [API]), and age at diagnosis (&gt; 65 years [y] vs. ≤ 65 y), using Kaplan-Meier log-rank analysis and Cox proportional hazards models. Independent sample t-tests and chi-square analyses were used for univariate comparisons. <em>P</em>-values &lt; <em>.</em>05 were considered statistically significant.</div></div><div><h3>Results</h3><div>A total of 5142 patients with aUC were identified. 1419 were (28%) female and 575 (11%) were &gt; 65 y. Of those with recorded race (<em>n</em> = 3492), 1% were API, 5% Black, 14% categorized as “other,” and 80% White. There was no difference in PFS (8.7 vs. 9.0 months [m], HR1.03; <em>P</em> = <em>.</em>82) or OS (13.2 vs. 13.5 m; HR1.05, <em>P</em> = <em>.</em>31) between women and men. Women had shorter PFS to men on immune checkpoint inhibitors (ICI) (<em>P</em> = <em>.</em>002) but not with other first-line (1L) therapy. API patients had comparable PFS (9.6 vs. 8.9 m; HR0.91; <em>P</em> = <em>.</em>45) but longer OS (28.5 vs. 14.1 m; HR0.56; <em>P</em> = <em>.</em>008) compared to White patients. Black patients had comparable PFS (7.9 vs. 8.5; HR1.06; <em>P</em> = <em>.</em>81) and OS (11.5 vs. 14.1 m; HR1.32; <em>P</em> = <em>.</em>73) vs White patients. Patients &gt; 65 y had shorter PFS to ≤ 65 y (7.6 vs. 9.0 m; HR1.14, <em>P</em> = <em>.</em>019); however, OS was longer in older patients (16.5 vs. 12.8 m; HR0.80, <em>P</em> &lt; <em>.</em>001). Only on 1L ICI, OS was longer in those &gt; 65 y compared to those ≤ 65 y (HR0.71; <em>P</em> = <em>.</em>021)</div></div><div><h3>Conclusion</h3><div>In this large real-world database, female aUC patients had comparable PFS and OS to males. API patients showed superior OS to White patients. Patients &gt; 65 y had inferior PFS but superior OS to patients ≤ 65 y.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 5","pages":"Article 102395"},"PeriodicalIF":2.3,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144694712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Influence of Chronic Kidney Disease on the Management of Upper Urinary Tract Cancer Following Radical Nephroureterectomy: A Nationwide Multi-Institutional Study","authors":"Chih-Chin Yu ,&nbsp;Steven K. Huang ,&nbsp;Wen-Hsin Tseng ,&nbsp;Hung-Lung Ke ,&nbsp;Wei-Ming Li ,&nbsp;Chao-Hsiang Chang ,&nbsp;Wen-Chi Chen ,&nbsp;I-Hsuan Alan Chen ,&nbsp;Jen-Tai Lin ,&nbsp;Jen-Shu Tseng ,&nbsp;Wun-Rong Lin ,&nbsp;Jian-Hua Hong ,&nbsp;Chao-Yuan Huang ,&nbsp;Shian-Shiang Wang ,&nbsp;Chuan-Shu Chen ,&nbsp;Ian-Seng Cheong ,&nbsp;Cheng-Huang Shen ,&nbsp;Chung-You Tsai ,&nbsp;Pai-Yu Cheng ,&nbsp;Yuan-Hong Jiang ,&nbsp;Yao-Chou Tsai","doi":"10.1016/j.clgc.2025.102394","DOIUrl":"10.1016/j.clgc.2025.102394","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to investigate the impact of chronic kidney disease (CKD) on oncological outcomes in patients with upper tract urothelial cancer (UTUC) undergoing radical nephroureterectomy (RNU) in Taiwan.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study using data from the Taiwan UTUC Collaboration database. 1590 patients who underwent RNU for UTUC were included in the analysis. Patients were categorized into 2 groups: those with adequate renal function and those with preoperative CKD. Overlap weighting was employed to address potential biases and baseline imbalances between the groups. Multivariable Cox regression models were used to analyze overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS).</div></div><div><h3>Results</h3><div>Preoperative CKD was significantly associated with poorer overall survival (HR, 1.372; 95% CI, 1.060-1.775; <em>P</em> = .016) compared to patients with adequate renal function. However, no significant association was observed between CKD and CSS or DFS. Further analysis revealed that patients with advanced CKD had a higher risk of UTUC-related death due to competing risks of non-UTUC-related mortality.</div></div><div><h3>Conclusions</h3><div>Preoperative CKD in UTUC patients undergoing RNU emerged as the sole risk factor for an inferior OS, without impacting CSS and DFS.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 5","pages":"Article 102394"},"PeriodicalIF":2.7,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis, Treatment and Survival From Penile Cancer: Real-World Data From the National Health Service England Between 2013 and 2020","authors":"Karl H. Pang ,&nbsp;Hussain M. Alnajjar ,&nbsp;Asif Muneer","doi":"10.1016/j.clgc.2025.102393","DOIUrl":"10.1016/j.clgc.2025.102393","url":null,"abstract":"<div><h3>Introduction</h3><div>The NHS National Disease Registration Service (NDRS) collects and curate data on cancer diagnoses. We report data for patients diagnosed with penile cancer (PeCa) in England between 2013 and 2020.</div></div><div><h3>Patient and Methods</h3><div>Data were extracted from the NDRS “Get Data Out” database. The incidence per year, route to diagnosis (RTD), treatment modalities and overall survival were analyzed.</div></div><div><h3>Results</h3><div>4,268 men were diagnosed with PeCa between 2013 and 2020. The number of diagnoses increased from 485 in 2013 to 635 in 2019 (30.9% increase). 2168 (50.8%) patients had stage I-II disease and 824 (19.3%) had stage III-IV disease. The stage was unknown in 1,276 (29.9%) cases. The majority were diagnosed through the 2-week-wait (2ww) referral pathway (<em>n</em> = 1072, 34.2%) or via GP referrals (<em>n</em> = 1083, 34.6%). 263 (8.4%) patients presented as emergencies, with this RTD being more common in men aged ≥70 years (<em>P</em> = .04) or men with stage III-IV (<em>P</em> = .01). The most common treatment modality was surgery alone (<em>n</em> = 3,391, 79.5%). 56 (1.3%) men had radiotherapy and/or chemotherapy alone, which was more common in stage III-IV disease. At 12, 24 and 60 months, overall survival across all years was 86.3%, 77.6% and 63.8% respectively. Survival remained relatively stable over time. Patients aged ≥70 years (<em>P</em> &lt; .0001) or with stage III-IV (<em>P</em> &lt; .0001) had poorer survival.</div></div><div><h3>Conclusion</h3><div>The NDRS provides valuable data on the rising incidence of PeCa, RTD, treatment and survival in England. Most of the patients were diagnosed through the 2ww or GP referral routes. Surgery was the primary treatment modality and survival remained stable over time.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 5","pages":"Article 102393"},"PeriodicalIF":2.7,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study","authors":"Neal D. Shore ,&nbsp;K. Kent Chevli ,&nbsp;Daniel Saltzstein ,&nbsp;Yaron Ehrlich ,&nbsp;Jay D. Raman ,&nbsp;Boris Friedman ,&nbsp;Alexander Sankin ,&nbsp;Douglas Scherr ,&nbsp;William C. Huang ,&nbsp;Michael J. Louie ,&nbsp;Sunil Raju ,&nbsp;Brent Burger ,&nbsp;Andrew Meads ,&nbsp;Mark Schoenberg ,&nbsp;OPTIMA II Study","doi":"10.1016/j.clgc.2025.102392","DOIUrl":"10.1016/j.clgc.2025.102392","url":null,"abstract":"<div><h3>Introduction</h3><div>The OPTIMA II phase 2b study (NCT03558503) treated patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) with UGN-102, a reverse thermal hydrogel containing mitomycin. Efficacy and safety results have been reported for the 12-month parent study; here, we report 5-year follow-up data.</div></div><div><h3>Patients and Methods</h3><div>Patients who participated in the OPTIMA II study and achieved a complete response (CR) after 6 weekly doses of UGN-102 were followed for up to 9 months after initial CR. Those with CR at study completion were eligible to enroll in a further long-term follow-up (LTFU) study, during which there were no protocol-specified interventions/treatments, protocol-specified visits, or evaluations. Supervising physicians provided semiannual updates on patients’ disease status. Duration of response (DoR) was calculated using the Kaplan–Meier method.</div></div><div><h3>Results</h3><div>Of the 41 patients achieving a CR at 3 months, 25 remained in CR at 12 months and 17 entered LTFU. For the 41 patients achieving a CR at 3 months the median Kaplan–Meier estimate of DoR was 24.2 months (95% confidence interval [CI], 9.72-42.09), with a median follow-up time of 35.8 months (95% CI, 10.78-60.98). For the 17 patients in the LTFU study the median DoR was 42.1 months (95% CI, 24.18-not estimable [NE]), with a median follow-up of 50.40 months (95% CI, 26.97-NE),</div></div><div><h3>Conclusion</h3><div>These results demonstrate that treatment with UGN-102 results in clinically meaningful, and highly durable response in patients with LG-IR-NMIBC. UGN-102 may offer a promising non-surgical alternative to transurethral resection of bladder cancer (TURBT) for LG-IR-NMIBC patients.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 5","pages":"Article 102392"},"PeriodicalIF":2.7,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144762681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of miR-181a-5p and its Target Genes in the Progression of Clear Cell Renal Cell Carcinoma and Association With the Immune Microenvironment","authors":"Huaxi Liu ,&nbsp;Guanfeng Luo ,&nbsp;Bei Xie ,&nbsp;Meilin Chen ,&nbsp;Penghui Xie ,&nbsp;Xiaoshan Zhao ,&nbsp;Yanting You ,&nbsp;Xiaomin Sun","doi":"10.1016/j.clgc.2025.102390","DOIUrl":"10.1016/j.clgc.2025.102390","url":null,"abstract":"<div><h3>Background</h3><div>Clear cell renal cell carcinoma (ccRCC) is one of the most predominant pathological types of renal cell carcinoma (RCC), with a high metastatic rate and poor prognosis. There is growing appreciation that miR-181a-5p plays a crucial role in various cancers, but the relevance of miR-181a-5p to disease progression in ccRCC and its mechanism of action in ccRCC remain poorly reported in detail. This study purposed to explore new biomarkers related to the prognosis of ccRCC and to uncover their potential mechanisms in influencing ccRCC progression.</div></div><div><h3>Methods</h3><div>The dbDEMC and GEO databases were used to screen differential miRNAs and differential genes in ccRCC, respectively. KEGG pathway analysis was performed to further search for differential genes in ccRCC. The miRWalk database was used to predict target genes of miR-181a-5p. The miR-181a-5p and its target genes expression, clinicopathological correlation, prognosis analysis, and immune infiltration correlation were performed in the data obtained from TCGA. STRING database was performed to construct a PPI network of the target genes of miR-181a-5p and immune-related genes of ccRCC from TISIBD database. In <em>vitro</em> experiments were conducted to verify the effect of miR-181a-5p on the growth, invasion and migration of ccRCC cells and to verify the target genes of miR-181a-5p.</div></div><div><h3>Results</h3><div>As a differential miRNA of ccRCC, miR-181a-5p is significantly up-regulated in ccRCC patients and has a high diagnostic accuracy. High expression of miR-181a-5p is related to poor progress free interval (PFI). KIT, MECOM, COL4A6, EGF, and MAPK10 are the target genes of miR-181a-5p, which are significantly down-regulated in ccRCC patients and have high diagnostic accuracy. Low expression of these genes is associated with disease progression and poor prognosis of ccRCC. In addition, miR-181a-5p and its target genes were found to be associated with the immune infiltration of ccRCC. In <em>vitro</em> experiments proved that miR-181a-5p promote the growth, invasion and migration of ccRCC cells, and it was found that COL4A6, EGF, and MAPK10 are more likely to be the target genes of miR-181a-5p.</div></div><div><h3>Conclusions</h3><div>MiR-181a-5p may work together with its target genes to affect tumor-induced immune cell infiltration, and thus affect ccRCC. MiR-181a-5p and its target genes, such as EGF and MAPK10, may be novel prognostic markers and therapeutic targets for ccRCC patients.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 5","pages":"Article 102390"},"PeriodicalIF":2.7,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}